Parker-Hannifin Corp (PH) Stock News

PulteGroup (PHM) has received a Zacks Rank #5 (Strong Sell) rating due to declining earnings estimate revisions and negative year-over-year performance. The homebuilder is expected to see earnings decline 15.8% for the current fiscal year, with consensus estimates revised down 4.4% over the past month. Revenue is also projected to decline 8% for the current fiscal year, though the stock is valued at par with peers.

The iShares U.S. Pharmaceuticals ETF (IHE) has outperformed VanEck Pharmaceutical ETF (PPH) over the past year, driven by concentrated exposure to Eli Lilly's GLP-1 drugs, delivering 38.2% returns versus PPH's 26.4%. However, PPH offers global diversification with European pharma giants, a higher dividend yield of 1.9%, and nearly identical expense ratios. IHE suits investors seeking recent momentum, while PPH appeals to those prioritizing international exposure and income.

State Street's XPH and Simplify's PINK offer two distinct approaches to healthcare investing. XPH provides lower-cost, passive pharmaceutical exposure with stronger recent returns (30.5% vs 18.3%), while PINK offers active, broader healthcare management with higher dividend yield (0.8% vs 0.4%) and lower volatility. PINK uniquely donates its management fees to breast cancer research. XPH suits cost-conscious pharma investors, while PINK appeals to those seeking active management and philanthropic impact.

RSPH (Invesco S&P 500 Equal Weight Health Care ETF) and IBB (iShares Biotechnology ETF) offer different approaches to healthcare investing. RSPH provides broader, equal-weighted healthcare exposure with lower volatility, higher dividend yield (0.6%), and a lower expense ratio (0.4%), making it suitable for risk-averse investors. IBB offers concentrated biotech exposure with stronger recent returns (35.5% vs 31.9%) but higher volatility and drawdown risk. The choice depends on investor risk tolerance and conviction in biotechnology's momentum.

Amphenol (APH) is highlighted as an attractive growth stock with a Zacks Rank #2 (Buy) and Growth Score of B. The company demonstrates strong fundamentals including projected EPS growth of 59.6% (vs. industry average of 37.3%), year-over-year cash flow growth of 75.8% (vs. industry average of 45.4%), and positive earnings estimate revisions. These metrics position the stock well for potential outperformance among growth investors.

Novarc Technologies will showcase its Physical AI welding automation solutions at FABTECH 2026, including the NovAI Suite for adaptive welding, SWR-TIGMIG dual-process pipe welding robot, and NovPlan automated programming software. The company has partnered with Yaskawa and ABB to demonstrate AI-powered vision and adaptive control capabilities designed to address fabrication industry challenges including skilled labor shortages and part variability.

Enphase Energy stock declined 4.02% on October 12, 2026, outpacing the broader market's 0.06% loss. The solar technology company has lost 9.74% over the past month. Analysts expect significant headwinds ahead, with earnings per share projected to decline 47.78% year-over-year and revenue expected to fall 26.05%. The company holds a Zacks Rank of #4 (Sell) with a Forward P/E of 17.12, trading at a premium to its industry average of 13.59.

The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio), higher dividends (1.9% yield), and a concentrated portfolio of 26 pharmaceutical companies with an established 15-year track record. Simplify Health Care ETF (PINK) provides broader healthcare exposure through active management of 58 positions with a unique charitable structure donating profits to cancer research, though it carries higher fees (0.51%) and lower yields (0.8%). For most long-term investors, PPH is recommended for its fundamentals, while PINK appeals to those seeking active management and charitable impact.

SPHD is a passively managed ETF with $3.17 billion in assets offering exposure to large-cap value stocks with high dividends and low volatility. With a 0.3% expense ratio, 5.12% dividend yield, and a Zacks ETF Rank of 3 (Hold), it presents a moderate risk option for long-term investors. However, larger competitors like SCHD and VTV offer lower expense ratios and significantly more assets under management.

PulteGroup (PHM), a homebuilder, is trending among investors but faces headwinds with a -7% return over the past month versus the S&P 500's +0.6% gain. The company is expected to report declining earnings (-11.2% YoY for current quarter and -11.9% for fiscal year) but shows recovery potential with +9.6% growth projected for next fiscal year. With a Zacks Rank #3 (Hold) rating and a B valuation grade indicating the stock trades at a discount to peers, PHM is expected to perform in line with the broader market in the near term.

The Invesco Water Resources ETF (PHO) offers diversified exposure to the Industrials-Water segment with $1.9 billion in assets and a 0.59% expense ratio. The ETF has declined 2.91% year-to-date and 5.81% over the past year, with a medium risk profile (beta 0.95). It carries a Zacks ETF Rank of 3 (Hold), making it a sufficient but not exceptional option compared to alternatives like CGW and FIW.

The VanEck Pharmaceutical ETF (PPH) offers low-cost exposure to the healthcare-pharma sector with a 0.36% expense ratio and $1.01 billion in assets. The fund tracks the MVIS US Listed Pharmaceutical 25 Index and holds major pharmaceutical companies like Eli Lilly, Merck, and Novartis. With a Zacks ETF Rank of 3 (Hold), year-to-date gains of 6.51%, and a medium-risk profile, PPH is presented as a reasonable option for investors seeking diversified pharma exposure, though alternative ETFs like FTXH and IHE are also available.

LEPAS, Chery Auto's premium new energy vehicle brand, officially launched the LEPAS L8 PHEV in Romania on September 30, 2026, opening its first flagship store in Sibiu. The vehicle features a 1040 km WLTP range, advanced comfort features, and starts at €45,500, with launch incentives offering €3,000 discounts for the first 100 buyers. LEPAS partnered with Materom for local distribution and after-sales services.

LEPAS, the premium NEV brand of Chery Auto, officially launched the LEPAS L8 PHEV in Romania on September 30, 2026, and opened its first flagship store in Sibiu. The vehicle features a 1,040 km WLTP range, advanced comfort features, and is priced from €45,500, with introductory offers for early buyers. The company partnered with Materom for local distribution and service support.

LEPAS, Chery Auto's premium electric vehicle brand, officially launched the L8 PHEV in Romania on September 30, opening its first flagship store in Sibiu. The vehicle features advanced hybrid technology with 1,040 km WLTP range and starts at €45,500, with launch incentives for early buyers. LEPAS partnered with Materom for local distribution and after-sales services.

LEPAS, Chery Auto's premium NEV brand, officially launched the LEPAS L8 PHEV in Romania on September 30, 2026, opening its first flagship store in Sibiu. The vehicle features a 1,040 km WLTP range, advanced comfort features, and starts at €45,500 with introductory offers including €3,000 discount for the first 100 buyers. LEPAS partnered with Materom for local distribution and after-sales services.

LEPAS, Chery Auto's premium new energy vehicle brand, launched the LEPAS L8 PHEV in Romania on September 30, 2026, opening its first flagship store in Sibiu. The vehicle features advanced hybrid technology with 1,040 km WLTP range and 2.2 L/100 km consumption. LEPAS partnered with Materom for local distribution, after-sales service, and spare parts supply. Launch pricing starts at €45,500, with early buyer incentives including €3,000 discount and 0.99% financing.

Chery Auto's premium NEV brand LEPAS launched the LEPAS L8 PHEV in Romania on September 30, 2026, opening its first flagship store in Sibiu. The vehicle features a 2,800mm wheelbase, advanced comfort features, and delivers a 1,040 km WLTP range. Priced at €45,500 (€42,500 with launch incentives), LEPAS partnered with Materom for local distribution and after-sales support.

VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio) and higher dividend yield (2%), making it better for long-term buy-and-hold investors. Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (41% vs 31%) with more balanced U.S.-focused holdings, but charges higher fees (0.58%) and offers lower yield (0.9%).

A securities class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly stated coverage would begin July 1, 2026, while concealing material adverse facts about the actual timeline, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

A class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product (neffy) with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to adequately disclose risks that the deadline might not be met, potentially impacting summer and back-to-school sales.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about expected July 1, 2026 coverage, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

A securities class action lawsuit has been filed against Park Ha Biological Technology Co., Ltd. for allegedly making materially false statements and failing to disclose a fraudulent stock promotion scheme involving social media misinformation and artificially manipulated trading activity. Investors who purchased securities between December 27, 2024 and July 8, 2025 are encouraged to seek legal counsel before the September 28, 2026 lead plaintiff deadline.

Rosen Law Firm announces class action securities lawsuits against ARS Pharmaceuticals (SPRY) and Datavault AI (DVLT), with October 5, 2026 deadline for investors to join. ARS Pharmaceuticals is accused of providing misleading statements regarding insurance coverage expansion timeline for its epinephrine spray product neffy through CVS Caremark, allegedly causing investors to purchase shares at artificially inflated prices.

PulteGroup (PHM) rose 2.79% in recent trading but faces headwinds with an 8.21% monthly decline. Analysts expect Q3 2026 earnings of $2.63 per share, down 11.15% year-over-year, and full-year earnings projected to fall 11.89%. The stock trades at a Forward P/E of 11.81, below its industry average of 13.05, earning a Zacks Rank #3 (Hold) rating. The homebuilding sector remains weak, ranked in the bottom 5% of industries.

A securities class action lawsuit has been filed against ARS Pharmaceuticals (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about a July 1, 2026 coverage start date, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm announces a securities class action lawsuit against Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) for investors who purchased securities between December 27, 2024 and July 8, 2025. The lawsuit alleges that defendants made materially false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, impersonated financial professionals, and artificially manipulated trading activity. The lead plaintiff deadline is September 28, 2026.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing misleading statements to investors regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company reportedly made confident statements about July 1, 2026 coverage while concealing material adverse facts, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

Vertiv (VRT) reported strong Q2 2026 results with product revenue rising 22% to $2.65B, driven by surging demand for AI data-center infrastructure. The company is expanding capacity globally and investing in advanced thermal and power solutions. However, it faces increasing competition from Super Micro Computer and Amphenol, both expanding their AI infrastructure portfolios. VRT stock has surged 47.8% year-to-date but trades at a premium valuation with a P/B ratio of 19.37X.

PulteGroup (PHM) declined 1.61% on September 16, 2026, underperforming the S&P 500's 0.45% loss. The homebuilder has fallen 5.22% over the past month, significantly trailing the broader market. Upcoming earnings on October 22 are expected to show declining performance with EPS projected at $2.63 (down 11.15% YoY) and revenue of $4.12 billion (down 6.4% YoY). The stock holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 11.86, trading at a discount to its industry average.